Skip to content

is shadbindutaila nasya more effective than anutaila nasya along with elakanadi kashaya in the management of DushtaPratishyaya-

COMPARATIVE STUDY OF EFFICACY OF SHADBINDU TAILA NASYA AND ANUTAILA NASYA ALONG WITH ELAKANADI KWATHA IN THE MANAGEMENT OF DUSHTA PRATISHYAYA-CHRONIC RHINOSINUSITIS

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/03/024393
Enrollment
60
Registered
2020-03-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J329- Chronic sinusitis, unspecified

Interventions

Intervention1: shadbindu taila nasya along with elakanadi kwatha: 2 sitting of Shadbindu taila Nasya with a gap of 7 days in between. one sitting will be for 7 days dose:6 drops in each nostril elakan

Sponsors

nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: -Patients fulfilling the diagnostic criteria which are based on symptomatology of Dushta Pratishyaya â?? Chronic Rhinosinusitis explained in classics will be selected - Patients with history of sinusitis minimum of 12 weeksâ?? duration - Patients between the ages of 20-60 years

Exclusion criteria

Exclusion criteria: - Patients not willing to participate in clinical trial. - Cases with nasal polyp causing complete obstruction of nasal cavity

Design outcomes

Primary

MeasureTime frame
Reduction in the signs and symptoms of Dushta Pratishyaya - Chronic RhinosinusitisTimepoint: assessement will be done on 1st day 15 th day 30 th day and on 45th day

Secondary

MeasureTime frame
1.Changes in the hematological findings i.e. TC, DC, ESR and Hb%, CRP. 2. Changes in the X-Ray PNS findings Timepoint: 45 days

Countries

India

Contacts

Public ContactDr Narayan Bavalatti

ALL INDIA INSTITUTE OF AYURVEDA

eyenimi@gmail.com9650715615

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026